US Patent

US9670492 — Modulation of prekallikrein (PKK) expression

Composition of Matter · Assigned to Ionis Pharmaceuticals Inc · Expires 2034-08-28 · 8y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

Ionis Pharmaceuticals Inc. has patented antisense compounds and methods to decrease prekallikrein (PKK) expression.

USPTO Abstract

Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.

Drugs covered by this patent

donidalorsen-sodium (DONIDALORSEN SODIUM)

Patent Metadata

Patent number: US9670492
Jurisdiction: US
Classification: Composition of Matter
Expires: 2034-08-28
Drug substance claim: Yes
Drug product claim: No
Assignee: Ionis Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.